Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Open accessAbstract
The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
It is currently unclear if asthma is indeed a risk factor for COVID-19 complications, and studies so far have not conclusively observed the expected increase in incidence.
“However, it is currently unclear if asthma is indeed a risk factor for COVID-19 complications (Hosoki et al., 2020), and studies so far have not conclusively observed the expected increase in incidence.”
From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Hosoki et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 203 · Cited by 63
Research works printed but not linked: 1
- [19]National Institutes of Health COVID-19 treatment guidelines Available at: https://covid19treatmentguidelines.nih.gov/introduction/ Accessed April 19, 2020 34003615
- Authors
- Hosoki, K., Chakraborty, A., & Sur, S.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Sur, Sanjiv
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 146
- Issue
- 2
- Pages
- 285-299
- ISSN
- 0091-6749 (ISSN-L)
- PMC
- PMC7331543
- OpenAlex
- W3038765308
- Cited by
- 63
- References
- 203
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 10 · 2022: 10 · 2021: 26 · 2020: 11
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Allergy and Clinical Immunology (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (3R01HL145477-01S1)
- U.S. Department of Defense (PR171425 W81XWH-18-1-0743)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Keywords
- COVID-19 pandemic, SARS-CoV-2, angiotensin-converting enzyme 2 receptor, spike protein receptor-binding domain, TMPRSS2, virus transmission, asymptomatic transmission, PCR testing, antibody detection, allergic rhinitis, asthma, asthma endotypes, COVID-19 risk factors, drug repurposing, remdesivir, pandemic mitigation strategies, face masks, social distancing
- MeSH terms
- Betacoronavirus, Physical Distancing, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, COVID-19 Testing, COVID-19 Drug Treatment, Adenosine Monophosphate, Age Factors, Alanine, Antiviral Agents, Asthma, Clinical Trials as Topic, Humans, Peptidyl-Dipeptidase A, Masks, Pneumonia, Viral, Quarantine, Receptors, Virus, Severity of Illness Index, Prevalence, Coronavirus Infections, Clinical Laboratory Techniques, Drug Repositioning, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review